GlassScriptPhysician profile
Aimee Dinh
NPI 1881424166
$2,104.44
in general payments reported to CMS, 2019-2025
15 companies · $1,690 in 2025
The $1,690 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $414 · 2025: $1,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.45 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $638.36 | 2024-2025 | |
| Janssen Biotech, INC. | $247.74 | 2024-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $223.22 | 2024-2025 | Saphnelo |
| Ucb, INC. | $207.96 | 2024-2025 | Bimzelx |
| Amgen INC. | $196.78 | 2024-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $117.70 | 2025 | |
| Lilly USA, LLC | $98.81 | 2024-2025 | Olumiant, Taltz, Zepbound |
| Genentech USA, INC. | $83.36 | 2024-2025 | Actemra |
| Actelion Pharmaceuticals US, INC. | $72.30 | 2025 | Uptravi, Opsumit, Opsynvi |
| Glaxosmithkline, LLC. | $67.15 | 2024-2025 | Benlysta |
| Pfizer INC. | $55.44 | 2025 | |
| Aurinia Pharma U.S., INC. | $36.40 | 2024-2025 | Lupkynis |
| Kyowa Kirin, INC. | $26.85 | 2025 | |
| Celltrion USA INC. | $16.49 | 2025 | Vegzelma |
| Tonix Medicines, INC. | $15.88 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Dinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.